Sarepta Therapeutics (NASDAQ:SRPT) Stock Breaks Above 200 Day Moving Average – Time to Sell?

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $18.78 and traded as high as $18.89. Sarepta Therapeutics shares last traded at $18.89, with a volume of 2,225,764 shares changing hands.

Analyst Upgrades and Downgrades

SRPT has been the subject of several analyst reports. William Blair upgraded shares of Sarepta Therapeutics to a “hold” rating in a report on Wednesday, September 23rd. Wall Street Zen lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Piper Sandler decreased their price objective on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a research report on Thursday, July 9th. HC Wainwright reiterated a “sell” rating and set a $5.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, October 5th. Finally, Needham & Company LLC reissued an “underperform” rating on shares of Sarepta Therapeutics in a research note on Monday, September 28th. Seven equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and seven have issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $22.88.

Sarepta Therapeutics Stock Down 0.5%

The firm has a market cap of $2.03 billion, a price-to-earnings ratio of -6.63, a PEG ratio of 0.32 and a beta of 0.38. The firm has a 50 day moving average of $19.26 and a 200 day moving average of $18.76. The company has a quick ratio of 2.62, a current ratio of 4.42 and a debt-to-equity ratio of 0.55.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.42. The firm had revenue of $401.25 million for the quarter, compared to analyst estimates of $366.39 million. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%. The company’s revenue was down 34.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.02 earnings per share. As a group, sell-side analysts predict that Sarepta Therapeutics, Inc. will post 3.27 earnings per share for the current year.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of large investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Sarepta Therapeutics in the third quarter valued at approximately $98,000. State of Wyoming bought a new stake in Sarepta Therapeutics during the third quarter worth $122,000. China Universal Asset Management Co. Ltd. grew its holdings in Sarepta Therapeutics by 114.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 85,939 shares of the biotechnology company’s stock worth $1,602,000 after buying an additional 45,837 shares in the last quarter. Pinnacle Wealth Planning Services Inc. grew its holdings in Sarepta Therapeutics by 50.6% during the third quarter. Pinnacle Wealth Planning Services Inc. now owns 1,780 shares of the biotechnology company’s stock worth $32,000 after buying an additional 598 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its position in Sarepta Therapeutics by 40.0% in the 3rd quarter. Nisa Investment Advisors LLC now owns 4,555 shares of the biotechnology company’s stock valued at $83,000 after buying an additional 1,301 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs use RNA-based technologies, gene therapy and other genetic approaches to address the underlying causes of serious neuromuscular disorders.

The company’s primary focus is Duchenne muscular dystrophy (DMD), a progressive genetic disease that causes muscle weakness and loss of function. Sarepta markets Exondys 51 (eteplirsen), Vyondys 53 (golodirsen) and Amondys 45 (casimersen), RNA-based therapies designed to help certain patients produce a shortened but functional form of dystrophin.